[July 31, 2015]

Research and Markets: Hypercholesterolemia Therapeutics Pipeline Review, H1 2015 - Analysis of 31 Companies & 59 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/238g66/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain cometitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Aegerion Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• Amgen Inc.
• AtheroNova Inc.
• Bristol-Myers Squibb Company
• Catabasis Pharmaceuticals, Inc.
• Cerenis Therapeutics Holding SA
• CrystalGenomics, Inc.
• CymaBay Therapeutics, Inc.
• Daewon Pharm Co. Ltd.
• Dybly AG
• Eli Lilly and Company
• Esperion Therapeutics, Inc.
• F. Hoffmann-La Roche Ltd.
• Hanmi Pharmaceuticals, Co. Ltd.
• Immune Response BioPharma, Inc.
• Johnson & Johnson
• Kadmon Corporation, LLC
• Kowa Company, Ltd.
• Merck & Co., Inc.
• Michigan Life Therapeutics, LLC
• Novartis AG
• Pfizer Inc.
• Planet Biotechnology Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Serometrix, LLC
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
• Thetis Pharmaceuticals LLC
• uniQure N.V.
• Zhejiang Hisun Pharmaceutical Co., Ltd.
  

For more information visit http://www.researchandmarkets.com/research/238g66/hypercholesterolem

View source version on businesswire.com: http://www.businesswire.com/news/home/20150731005502/en/

[ Back To TMCnet.com's Homepage ]